**Systematic Review**

**Milk Fat Globule Membrane Supplementation in Children: Systematic Review with Meta-Analysis**

Dominika Ambrożej 1,2, Karolina Dumycz 1,2, Piotr Dziechciarz 3 and Marek Ruszczyński 3, *

**Abstract:** (1) Background: Milk fat globule membrane (MFGM), composing fat droplets responsible for lipid transport in breast milk, has been shown to possess immunological and antimicrobial effects. Standard formulas (SF) are devoid of MFGMs during the production process. The study’s aim was to evaluate the safety and benefits of MFGMs supplementation in children. (2) Methods: We searched four databases for randomized controlled trials evaluating the supplementation of MFGMs in children. Growth parameters were chosen as the primary outcome. (3) Results: Twenty-four publications of seventeen studies were included. Meta-analyses assessing the primary outcomes at the age of 4 months included four studies (814 children) comparing the MFGM-supplemented formulas and SF, and two trials (549 children) comparing the MFGM-supplemented formulas and breastfeeding. The primary outcomes were non-inferior in all the experimental MFGM formulas compared to SF, or even represented more similar results to breastfed infants. The promising effects, including a lower incidence of acute otitis media and improved cognitive development, cannot be firmly confirmed due to the small amount of existing evidence. No significant adverse effects were reported in any of the assessed products. (4) Conclusions: The available data signaled beneficial effects and a good safety profile, requiring future research with well-designed trials.

**Keywords:** milk fat globule membrane; MFGM; feeding; infant formula; children

1. Introduction

Breastfeeding is the most effective and natural method of feeding to provide infants with valuable nutrients, immunomodulatory factors, and energy [1]. It has been long reported to have various protective effects against allergies, asthma, infections, and immune-mediated diseases in children [2,3]. The exact composition of human breast milk depends on various maternal factors and matches specific infant demands. The largest energy source in human milk forms lipids, which contribute approximately 40–55% of the total energy [4]. Lipids are secreted into breast milk by an exclusive mammary gland mechanism and are composed of fat droplets enclosed with a tri-layer membrane [5]. The core lipid consists mainly of triglycerides (98%), whereas the membrane, called milk fat globule membrane (MFGM), comprises a monolayer of polar lipids and a lipid bilayer. MFGM consists of phospholipids such as sphingomyelins, phosphatidylcholines, gangliosides, and different proteins, including lactoferrin or mucins [6].

An increasing body of evidence indicates that MFGM can exert a beneficial effect on immune functions, central nervous system development, and metabolism [7]. Standard formulas are devoid of bovine MFGMs due to the production process and are replaced by vegetable oils. This phenomenon may account for the differences observed between formula-fed and breastfed infants. Therefore, in recent years, efforts have been made...
to create standard formulas closely imitating human milk by adding bovine MFGM to
the composition.

The MFGMs-supplemented formulas are attracting an increasing interest due to
the reports on their favorable effectiveness on infants’ growth, risk of infections, cog-
nitive development, microbiome, and metabolism in comparison to standard formulas
and/or breastfeeding [8].

The purpose of this systematic review was to evaluate the safety and clinical benefits
of the MFGMs supplementation in children available from randomized controlled trials.

2. Materials and Methods

2.1. Search Strategy

The study followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines and was registered in the National Institute for Health
Research’s PROSPERO (CRD42020138870) [9].

We performed a systematic search and retrieved studies from PubMed, Web of Science,
Embase, and the Cochrane’s Library databases from inception to 20 October 2019. Addi-
tionally, the hand-search was conducted. We have repeated the same search on 18 July 2020
for new data through all previously used databases to keep our systematic review up to
date. The search terms with the filter validated in the Cochrane Handbook for randomized
controlled trials can be found in the Supplementary Materials (Table S1).

2.2. Study Selection

All extracted papers were imported into EndNote®reference manager Version x8
(Clarivate Analytics; 2016). Two reviewers working independently (D.A., M.R.) screened at
first the titles with abstracts and next assessed the potentially suitable full texts. Uncertainty
about the eligibility of studies for the review was resolved through discussion at each stage
with a third reviewer (P.D.). The final group of selected studies met the inclusion and
exclusion criteria pointed out herein.

2.3. Inclusion Criteria

Original studies were accepted only if they (1) were published in English; (2) were
performed on human beings aged less than 18 years old; (3) introduced MFGMs oral
supplementation performed in any available form; (4) involved any of the following
control groups: placebo or milk formula without supplementation; and (5) have been
performed as randomized controlled trials (RCTs).

2.4. Exclusion Criteria

We excluded (1) duplicate publications and (2) multiple publications of the same trial,
(3) conference abstracts, (4) study protocols, (5) nonhuman studies, and (6) trials in which
the MFGMs were administered during prenatal development.

2.5. Data Extraction

Data were independently extracted by three reviewers (D.A., K.D., and M.R.) using a
structured data collection form, collating relevant study details such as date of publication,
country of origin, study design, population of the study, intervention and comparison,
measurement points, results, and confounding factors. Actions were taken to contact
corresponding authors when additional clarification was required. Data were extracted
from all selected articles, regardless of whether the results were positive or negative, to
present a fair and unbiased account of the available published evidence.

2.6. Risk of Bias Assessment

Three independent reviewers (D.A., K.D., and M.R.) assessed the risk of bias, without
being blinded to the authors or journal, in each of the included studies. A revised Cochrane
risk-of-bias tool for randomized trials was used (RoB 2) [10], Figure S1. Encountered discrepancies were resolved through discussion of all the reviewers.

The RoB 2 tool is structured into five bias domains, which enables judging the randomization process, deviations from intended interventions, any missing outcome data, measurement of the outcome, and selection of the reported result.

The judgments for each domain were to choose between “low risk of bias”, “some concerns”, or “high risk of bias”. In conclusion, the overall bias was determined by reflecting the individual marks.

2.7. Data Synthesis

Required data were extracted from included studies to a predesigned Excel sheet in Microsoft Excel. Review Manager (RevMan) v5.3 software from the Cochrane Collaboration (London, UK) was used to perform meta-analyses, generate forest plots, and calculate the $I^2$ statistic. The data were pooled on baseline characteristics and outcomes using the meta-analysis approach. In the studies that reported continuous variables as means, mean difference (MD) was calculated. Heterogeneity was assessed using the $I^2$ statistic defined by the Cochrane Handbook for Systematic Reviews. Either Chi$^2$ test $p < 0.10$ or $I^2$ value > 50% indicated substantial heterogeneity.

Growth parameters such as weight, length/height, and head circumference were chosen as the primary outcome of our systematic review.

The secondary outcomes assessed in the review consisted of any additional outcomes reported in the included trials such as validated psychomotor development scales, any side effects, oral or gut microbiota shifts if reported, as well as any potential benefit on the infection/fever prevalence in children.

3. Results
3.1. Description of the Studies

Our initial search yielded 676 randomized controlled trials; after removing duplicates ($n = 185$), we identified 491 unique citations. The PRISMA flow chart is shown in Figure 1. The screening of titles and abstracts excluded 432 articles, rendering 59 trials to full-text assessment. Finally, 17 publications were included in our systematic review studies (Table 1). Data from three RCTs were eligible for the meta-analysis comparing anthropometric measurements in experimental vs. standard formula-fed infants [11–13], and two RCTs were eligible for meta-analysis comparing the same measurements in experimental formula vs. breast-fed infants [11,13].

All 10 clinical trials, including 3575 patients, were published in full text in peer-reviewed journals. Seven publications reported results from one clinical trial [11,14–19], and two publications reported results of another clinical trial [20,21]. Included trials were conducted in different parts of the world—five trials were conducted in Europe (Sweden, the Netherlands, Belgium, France, Italy, Spain) [11,12,21–23], one trial was conducted in South America (Peru) [24], and five trials were conducted in Asia (China, Indonesia, India, Singapore) [13,22,25–27]. Three of the trials were multicenter [12,22,23].

In most of the included trials, the overall risk of bias was considered as low [11–13] or only with some concerns [22,24,26] (Figure 2). However, two of the studies were judged as with a high risk of bias [20,23]. Their methodological concerns included poor data availability on randomization and blinding process, deviations from the intended intervention, and potentially missing outcome data, as well as some discrepancies in reporting results. Notably, a few papers did not present the results according the intention to treat (ITT) analysis, which may have led to the increased bias [20,23,25,27]. Another potential confounder was the lack of the beforehand published trial protocol in three cases [23–25].
Figure 1. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.

Figure 2. Cont.
Figure 2. The meta-analyses of growth parameters measured at 4 months of age between children fed with standard formula or breastfed and formulas supplemented with milk fat globule membrane (MFGM): (a) Weight comparing the experimental formulas (including MFGM) with the standard formulas; (b) Weight comparing the experimental formulas (including MFGM) with breastfeeding; (c) Length comparing the experimental formulas (including MFGM) with the standard formulas; (d) Length comparing the experimental formulas (including MFGM) with breastfeeding; (e) Head circumference comparing the experimental formulas (including MFGM) with the standard formulas; (f) Head circumference comparing the experimental formulas (including MFGM) with breastfeeding.

| Study or Subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI | Mean Difference IV, Fixed, 95% CI |
|-------------------|-------------------|----|-------|--------------|----|-------|--------|---------------------------------|---------------------------------|
| 4.1.1 Lacprodan® MFGM-10, Aroa Foods Ingredients Group | | | | | | | | | | |
| Billeul 2014 (MFGM-P, F) | 60.9 | 1.7 | 19 | 61.7 | 2.4 | 22 | 7.4% | -0.80 [0.26, 0.46] | |
| Billeul 2014 (MFGM-P, M) | | | | | | | | | |
| Li 2014 | 64.2 | 2.2 | 192 | 64.3 | 2.2 | 194 | 61.6% | -0.10 [-0.04, 0.04] | |
| Timby 2014 | 64.2 | 2 | 76 | 63.7 | 2.6 | 72 | 21.0% | 0.50 [-0.25, 1.25] | |
| Subtotal (95% CI) | 321 | | | 313 | | | 100.0% | 0.09 [-0.26, 0.43] | |
| Heterogeneity: $\chi^2 = 6.52, df = 3 (P = 0.09); I^2 = 54$ | | | | | | | | Test for overall effect: $Z = 0.49 (P = 0.62)$ | |
| 4.1.2 Different MFGM Supplement | | | | | | | | | |
| Billeul 2014 (MFGM-L, F) | 61.5 | 2.2 | 23 | 61.7 | 2.4 | 22 | 19.6% | -0.20 [-1.55, 1.15] | |
| Billeul 2014 (MFGM-L, M) | | | | | | | | | |
| Breg 2019 | 62.9 | 2.1 | 70 | 62.9 | 2.4 | 58 | 56.9% | 0.00 [-0.79, 0.79] | |
| Subtotal (95% CI) | 122 | | | | | | | 105.00% | 0.03 [-0.56, 0.63] | |
| Heterogeneity: $\chi^2 = 0.30, df = 2 (P = 0.86); I^2 = 0$ | | | | | | | | Test for overall effect: $Z = 0.10 (P = 0.92)$ | |
| (d) | | | | | | | | | |
| 2.2.1 Lacprodan® MFGM-10, Aroa Foods Ingredients | | | | | | | | | |
| Li 2019 | 64.2 | 2.3 | 192 | 64.3 | 2.1 | 218 | 70.1% | -0.10 [-0.53, 0.33] | |
| Timby 2014 | 64.2 | 2 | 76 | 64.1 | 2.1 | 73 | 29.9% | 0.10 [0.56, 0.76] | |
| Subtotal (95% CI) | 308 | | | 281 | | | 100.0% | -0.04 [-0.46, 0.32] | |
| Heterogeneity: $\chi^2 = 0.22, df = 1 (P = 0.62), I^2 = 0$ | | | | | | | | Test for overall effect: $Z = 0.22 (P = 0.83)$ | |
| 2.2.2 Different MFGM Supplement | | | | | | | | | |
| Breg 2019 | 62.9 | 2.1 | 70 | 63.2 | 2.1 | 65 | 100.0% | -0.30 [-1.01, 0.41] | |
| Subtotal (95% CI) | 70 | | | 65 | | | 100.0% | -0.30 [-1.01, 0.41] | |
| Heterogeneity: Not applicable | | | | | | | | Test for overall effect: $Z = 0.83 (P = 0.41)$ | |
| (e) | | | | | | | | | |
| 5.1.1 Lacprodan® MFGM-10, Aroa Foods Ingredients Group | | | | | | | | | |
| Billeul 2014 (MFGM-P, F) | 41.1 | 1.3 | 19 | 40.9 | 1.3 | 22 | 5.6% | 0.20 [-0.60, 1.00] | |
| Billeul 2014 (MFGM-P, M) | | | | | | | | | |
| Li 2019 | 41.3 | 1.2 | 192 | 41.5 | 1.2 | 194 | 62.4% | -0.20 [-0.44, 0.04] | |
| Timby 2014 | 41.7 | 1.2 | 76 | 41.6 | 1.1 | 72 | 22.0% | 0.10 [-0.30, 0.50] | |
| Subtotal (95% CI) | 321 | | | 312 | | | 100.0% | -0.09 [-0.28, 0.10] | |
| Heterogeneity: $\chi^2 = 2.26, df = 3 (P = 0.52); I^2 = 0$ | | | | | | | | Test for overall effect: $Z = 0.95 (P = 0.34)$ | |
| 5.1.2 Different MFGM Supplement | | | | | | | | | |
| Billeul 2014 (MFGM-L, F) | 40.9 | 1.1 | 23 | 40.9 | 1.3 | 22 | 20.9% | 0.00 [-0.71, 0.71] | |
| Billeul 2014 (MFGM-L, M) | | | | | | | | | |
| Breg 2019 | 41.2 | 1.2 | 70 | 41.5 | 1.3 | 58 | 54.3% | -0.30 [-0.74, 0.14] | |
| Subtotal (95% CI) | 122 | | | | | | | 104.00% | -0.14 [-0.46, 0.18] | |
| Heterogeneity: $\chi^2 = 1.20, df = 2 (P = 0.55); I^2 = 0$ | | | | | | | | Test for overall effect: $Z = 0.84 (P = 0.40)$ | |
| (f) | | | | | | | | | |
| 3.2.1 Lacprodan® MFGM-10, Aroa Foods Ingredients | | | | | | | | | |
| Li 2019 | 41.3 | 1.2 | 192 | 41.6 | 1.1 | 208 | 71.9% | 0.01 [-0.93, 0.96] | |
| Timby 2014 | 41.1 | 1.2 | 76 | 41.1 | 1.2 | 73 | 29.1% | 0.01 [-0.93, 0.96] | |
| Subtotal (95% CI) | 308 | | | 301 | | | 100.0% | 0.01 [-0.93, 0.96] | |
| Heterogeneity: $\chi^2 = 3.22, df = 1 (P = 0.07), I^2 = 69$ | | | | | | | | Test for overall effect: $Z = 2.12 (P = 0.0301)$ | |
| 3.2.2 Different MFGM Supplement | | | | | | | | | |
| Breg 2019 | 41.2 | 1.2 | 70 | 41.1 | 1.1 | 73 | 100.0% | 0.01 [-0.93, 0.96] | |
| Subtotal (95% CI) | 70 | | | 73 | | | 100.0% | 0.01 [-0.93, 0.96] | |
| Heterogeneity: Not applicable | | | | | | | | Test for overall effect: $Z = 0.12 (P = 0.60)$ | |
3.2. Populations

Most of the studies recruited participants below 2 months of age at inclusion. In the three remaining trials, older children were included (Table 1) [23,24,26].

3.3. Interventions

Clinical trials were heterogeneous concerning applied MFGM-containing formula in the intervention groups. In one clinical trial, two different MFGM-containing formulas were used—lipid-rich MFGM (MFGM-L) (Anmum Infacare, Fonterra) and protein-rich MFGM (MFGM-P) (Lacprodan MFGM-10, Arla Food Ingredients) [12]. In four clinical trials, the latter formula was applied [11,13,24,27]; however, in one of them, it was applied along with the addition of bovine lactoferrin [27]. In the remaining studies, various types of MFGM-containing experimental formulas were used (Table 1) [20,23,25,26]. The duration of the intervention varied among the studies from approximately 3 months through 4, 6, to 18 months.

3.4. Outcomes

The outcomes presented in the trials were highly heterogeneous in terms of the methods used to evaluate specific outcomes and time points of the assessment. In most of the trials’ anthropometric measurements (weight, length, head circumference, daily weight gain), cognitive development or infection prevalence were employed as the primary outcomes. Additional outcomes evaluated in the studies included adverse events, hematological and biochemical assessment, and oral and fecal microbiota.

Due to the heterogeneity of outcomes, most of the data were analyzed descriptively. Solely data on weight, length, and head circumference at four months of age were eligible for meta-analysis.

3.4.1. Anthropometric Measurements

- **Experimental formula compared to a standard formula**

  Data from the studies eligible for meta-analysis showed no differences in mean weight, length, and head circumference at the age of four months (Figure 2a,c,e) [11–13]. Furthermore, studies that were not included in the meta-analyses showed no differences in mean weight, length, head circumference, and mean weight gain [12,25,27]. Dissimilarities were also not shown with respect of weight-for-age, length-for-age, and weight-for-length z-scores [20,25].

- **Experimental Formula Compared to Breastfeeding**

  The conducted meta-analyses indicated that at the age of four months, children from the group fed with experimental formula (EF) had slightly lower mean body weight and head circumference compared to the breastfed (BF) infants (Figure 2b,f). Body length did not differ between the groups (Figure 2d) [11,13].

  Moreover, the comparison between BF and formula-fed (both EF + standard formula, SF) infants by Timby et al. revealed the significant interactions for z-scores for the weight \((p = 0.025)\) and length \((p = 0.003)\) [11]. On the other hand, Nieto-Ruiz et al. showed no statistically significant differences in mean weight, growth, daily weight gain, and no differences in several z-scores [20].

  In the research conducted by Billeaud et al., one control group of standard formula-fed infants served as a comparison to infants fed with MFGM-P and MFGM-L formulas (F—females, M—males, MFGM-P—standard formula enriched with a protein-rich MFGM fraction, MFGM-L—standard formula enriched with a lipid-rich MFGM fraction).

3.4.2. Psychomotor Development

According to the results of the evaluation of 6-month-old infants using the Griffiths Mental Development Scale (GMDS) by Gurnida et al., there was a significant increase in scores for Hand and Eye Coordination \((p = 0.006)\), Performance \((p < 0.001)\), and for General
IQ ($p = 0.041$) in the EF group. However, no significant difference was found between the EF and SF group for the Griffith Locomotor, Personal–Social, and Hearing and Speech scores. Remarkably, all scores in this group were similar to those of the BF group [25]. In two trials, infants’ psychomotor development was evaluated at 12 months of age using the Bayley Scales of Infant and Toddler Development (Bayley-III) scale [11,27]. Timby et al. reported significantly higher scores of EF compared to SF groups in the cognitive domain (mean difference $-4.0$, $95\%$CI $(-6.9498$ to $-1.0502)$, $p = 0.008$), but there were no differences compared to the BF group ($p = 0.35$). Moreover, BF infants performed significantly better in the verbal domain than both EF (mean difference $-4.1$, $95\%$ CI $(-7.6134$ to $-0.5866)$, $p = 0.029$) and SF infants (mean difference $-4.2$, $95\%$ CI $(-7.5807$ to $-0.8193)$, $p = 0.012$). No differences were reported in respect of the motor domain between any groups [11]. According to Li et al. EF-fed infants presented higher scores in the cognitive, language, and motor domains ($p < 0.01$; $p < 0.01$; $p < 0.01$) at 12 months of age. Differences did not persist until 18 months of age [27]. Nieto-Ruiz et al. indicated that children who had consumed EF during the first 18 months of life presented higher scores in the use of language (mean difference $-5.86$, $95\%$ CI $(-10.6048$ to $-1.1152)$ $p = 0.033$) and spontaneous oral expression (mean difference $-0.150$, $95\%$ CI $(-0.2998$ to $-0.0002)$ $p = 0.024$) than SF children according to the Oral Language Task of Navarra-Revised (PLON-R) test at the age of four [21]. Notably, Veereman et al. reported fewer behavioral problems assessed by parents using the Achenbach System of Empirically Based Assessment (ASEBA) questionnaire in children in the experimental group [23].

3.4.3. Risk of Infections

The impact of applied formulas or breastfeeding on the prevalence of infections was evaluated in two manners in the included studies—either as a secondary endpoint or as an adverse event. Timby et al. reported a lower incidence of acute otitis media in the EF group (MFGM-P) compared to the SF group ($p = 0.034$) as well as the incidence of antipyretic use ($p = 0.021$) [15]. Likewise, Li et al. showed a lower incidence of respiratory tract infections and diarrhea in the EF group compared to the SF group [27]. According to Li et al. and Gurnida et al., MFGM-formula-fed and SF-fed infants did not differ significantly with respect to various infections [13,25]. By contrast, Breji et al. reported a higher occurrence of diarrhea in the EF group compared to the SF group (13.4% vs. 7.8%), though without statistical significance [22]. Furthermore, Billeaud et al. showed a slight difference in the prevalence of infections between infants in experimental and control groups [12]. Children in the MFGM-P group presented a significantly higher rate of respiratory tract infection symptoms reported by parents after 2 months of the beginning of the study. There were no differences in the infection rate between MFGM formula-fed infants and BF infants (except for one MFGM-P group). Bovine MFGM and phospholipids added to chocolate milk in pre-school children showed a reduction of days with fever compared to the control group ($p < 0.028$); however, there was no significant influence on the incidence of diarrhea, constipation, cough, doctors’ visits, and days of school absence [23].

3.4.4. Prevention of Diarrhea in Developing Countries

Zavaleta et al. demonstrated a reduction of the number of bloody diarrhea episodes in the EF group as compared to the SF group ($p = 0.025$), although no significant effect on the longitudinal prevalence of diarrhea, duration of diarrhea episodes, and incidence of severe diarrhea episodes were reported in Peruvian infants. Furthermore, no differences in the pathogenesis of diarrhea were found (infection with different Escherichia coli serotypes, Campylobacter jejuni, Giardia lamblia, Blastocystis hominis, Rotavirus) [24]. Poppitt et al. reported no differences in the number, duration, and severity of all-cause diarrhea episodes between the EF and SF groups, however, the duration of rotavirus diarrhea was lower in the EF group ($p = 0.03$) throughout the intervention period [26].
3.4.5. Metabolic Effects

Metabolic effects of several formulas were extensively evaluated in the cohort of children primarily described by Timby et al. [11]. The first analysis revealed that EF and SF infants presented higher growth velocity than BF with concomitant higher plasma insulin and blood urea nitrogen level at six months of age [11]. Further analysis of lipidomics showed higher levels of triglycerides and cholesterol in serum, as well as higher low-density lipoprotein cholesterol: high-density lipoprotein cholesterol (LDL:HDL) ratios and leptin:fat mass ratios in BF infants compared to SF. The EF group also had a higher total serum cholesterol concentration than the SF group, reaching the level of the BF group [14]. Grip et al. indicated significant differences in the serum, plasma, and erythrocyte membrane concentrations of sphingomyelins, phosphatidylocholines, and ceramides at 4 and 6 months of age between infants from the EF and SF groups [17]. Moreover, He et al. demonstrated that the formula-fed infants presented a preference for protein metabolism, which was expressed by the higher serum levels of amino-acid catabolism products and low efficiency of amino-acid clearance. In contrast, BF infants had higher levels of fatty acid oxidation products, which account for fat metabolism preference. Interestingly, the EF group was characterized by higher levels of fat metabolism products than SF infants, which may bridge the gap between the EF and BF infants [18]. Metabolic differences were visible only during the exclusive feeding period and did not remain at 12 months of age [14,17,18].

Gurnida et al. revealed higher ganglioside serum concentrations in the EF group than SF (p < 0.01) but no significant differences between EF and BF infants at 6 months of age [25]. On the other hand, Billeaud et al. did not show any differences in plasma and red blood cell membrane levels of phospholipids, cardiolipin, cholesterol, insulin-like growth factor 1 (IGF-1), leptin nor IGF BP3 between EF and SF infants. However, the level of C-peptide was lower in both EF groups compared to SF (p = 0.03) [12].

3.4.6. Microbiome

The oral and fecal microbiome was evaluated in infants from the cohort primarily described by Timby et al. Assessment of oral microbiota using the bacterial 16S rRNA sequencing method revealed significantly higher microbial richness in formula-fed (EF + SF) compared to BF infants at 4 months of age. Moreover, infants fed with EF had a significantly lower level of Moraxella catarrhalis compared to the SF-fed group, which may be associated with fewer episodes of acute otitis media in the EF group [16]. Yet, He showed that BF infants had a more heterogenous fecal microbiome but only during the exclusive formula feeding period. After the introduction of weaning food with either EF, SF, or BF, no significant differences in fecal microbiome were observed [19].

3.4.7. Adverse Events

Treatment-emergent adverse events were reported as respiratory tract and gastrointestinal infections, skin diseases, and formula intolerance. Risk of respiratory tract and gastrointestinal infections was described in the Section 3.4.4, since in some of the trials, they were assessed in the character of primary outcomes. None of the studies raised the concerns of MFGM-supplemented formulas. No adverse events in constipation and skin diseases including eczema were reported by Li et al. [27], whereas an even lower rate of dry skin was noted in the EF group compared to SF (p = 0.08) by Breji et al. [22]. Li et al. reported a low number of adverse events without any differences between MFGM, both for the SF and BF groups. On the other hand, Billeaud et al. (MFGM-P) showed a significantly higher rate of eczema (p = 0.001) in infants consuming MFGM-P formula [12]. Other treatment-emergent adverse events did not differ between groups.
### Table 1. Characteristics of included studies.

| Study ID | Study Design and Analysis Method | Population | Sample size |FU (%) at the End of Intervention | Specific Assessment Point | Intervention and Duration | Comparison | Measurement Points | Primary Outcomes | Secondary Outcomes | Results |
|----------|----------------------------------|------------|-------------|----------------------------------|---------------------------|---------------------------|------------|-------------------|-----------------|------------------|---------|
| Zavaleta et al. [23] (Peru) 2011 | Double-blind RCT | Healthy, pre-school children, age 2.5–6 years-old | 253 children | 76% of children [4/5 intervention group] | 76% of children [4/5 control group] | 200 mL chocolate formula milk enriched with 250 mg of phospholipids with the addition of 2.5% of MFGM (INPULSE, Büllinger SA) | Duration: 4 months | (1) Diarrhea with daily reports collected every 2 weeks by study coordinator | Number of days with fever, diarrhea, coughing, and/or constipation | (1) Number of doctor visits (2) Medication intake (3) Number of missed school days (4) Acceptability of the study product | (1) No difference between groups for diarrhea, constipation, cough, doctor visits, and days of school absence, medication intake (2) The number of days with fever (≥38.5 °C) and the number of short (≤3 days) and long periods (≥4 days) fever were significantly lower in the intervention group (3) Lower C-peptide levels in the intervention group compared to control. There was no significant difference in groups for 9–10 months of age. |
| Gurnida et al. [25] (Indonesia) 2012 | Double-blind RCT | Healthy, term infants between 2 and 8 weeks of age with birth weight ≥2.5 kg | 110 infants | 85% of infants [4/5 intervention group] | 85% of infants [4/5 control group] | Standard formula added complex milk lipid to increase the ganglioside GD1a (Anmum MECOM-10, Arla Foods Ingredients) | Duration: from enrollment (2-8 weeks) until 6 months (24 weeks) | (1) Standard formula | Cognitive development as measured by the GMDS | (1) Anthropometric measurements (2) Serum laboratory measurements | (1) Significant increase in scores for Hand and Eye Coordination (p ≤ 0.001) and Performance (p ≤ 0.005) and also for Total Score (Karan AQ) (p ≤ 0.041) in the EF group but no differences between EF and BF group (2) No significant differences in anthropometric measurements between EF and BF groups (3) Significantly higher serum level of ganglioside C13 in the EF group compared to SF (p ≤ 0.01) with no difference between EF and BF groups |
| Veerman-Nijsten et al. [23] (Belgium, France, the Netherlands) 2012 | Double-blind RCT | Healthy, full-term infants, < 34 days of age, with a birth weight 2500–4500 g | 199 infants | 72.6% of infants [4/5 intervention group] | 72.6% of infants [4/5 control group] | Standard formula | Duration: Intervention from 14 ± (3) days of age to 4 months (day 112) = 11 weeks | Baseline visit [0–25 days], day 14 ± 2, 36 ± 6, 44 ± 7, 112 ± 7 plus 3 additional follow-up visits at 6, 8, and 12 months of age in France | Mean weight gain (g/day) from baseline (age 0–12 days) to age 112 days (age 4 months) with a non-inferiority margin of −3.0 g/day | (1) Anthropometric measurements (2) Plasma laboratory measurements (3) Immune response to Polio and Hib vaccines | (1) No significant differences in anthropometric measurements and plasma phospholipid, carbohydrates, cholesterol, and Tg levels. (2) Lower C-peptide levels in MFGM-F group compared to control formula (p ≤ 0.01) (3) Lower mean poliovirus type 1 IgG level in the MFGM-F group in Italy (p ≤ 0.04)
Table 1. Cont.

| Study ID | Study Design and Analysis Method | Population | Sample size + FU (%) at the End of Intervention or Specific Assessment Point | Intervention and Duration | Comparison | Measurement Points | Primary Outcomes | Secondary Outcomes | Results |
|----------|----------------------------------|------------|-------------------------------------------------------------------|---------------------------|------------|--------------------|------------------|-------------------|---------|
| Popitt et al. [26] (Sweden) 2015 | Double-blind RCT ITT analysis | Healthy infants <2 months of age, gestational age 37–42 weeks, birth weight 2500–4500 g | Inclusion: 420 infants Completed: 93% - 90% EF - 91% SF | Intervention: High ganglioside complex milk lipid supplement (Annum Infracare, Fonterra) added to fresh milk Duration: For 12 weeks | Control supplement added to fresh milk | Baseline; assessment by fieldworker twice a week (24 visits), after 12-week intervention | Total number of days with RVD during the intervention (1) Total number of days with diarrhea of any type (AUC) (2) Number of episodes, duration, and severity of RVD and ACD (3) ES lead in stool samples at baseline and 12-week | (1) Mean duration that RVD persisted was lower in the EF group (p = 0.01) (2) The reported prevalence of major illnesses during the period of 12 weeks was lower in the EF group (OR 3.5, 95% CI 1.9–7.9, p = 0.03) |
| Timby et al.* [14] (Sweden) 2015 | Double-blind RCT ITT analysis | Healthy infants <2 months of age, gestational age 37–42 weeks, birth weight 2500–4500 g | Inclusion: 240 infants Completed: 6 months of age: 92% of infants - 95% EF - 90% SF - 90% BF | Intervention: Experimental formula supplemented with protein-rich bovine MFGM (Lacprodan MFGM-10, Arla Foods Ingredients) Duration: From enrollment <2 months to 6 months of age, follow-up until 12 months of age | (1) Standard formula (2) Breastfeeding (reference group) | At inclusion, 4, 6, 12 months of age | (1) Cognitive level at 12 month using Bayley-III (2) Weight at 6 months (3) Anthropometric measurements (2) Plasma insulin | (1) Significantly higher cognitive development in EF group than in SF (p = 0.039) but not different from RR group (2) When groups were divided into RRH compared with formula-fed groups (EF > SF), significant interactions were found between group and time on z-scores for weight (p = 0.028) and length (p = 0.033) (3) Formula (EF + SF) fed infants had higher insulin plasma concentrations at baseline and 4.4 months compared to RR group |
| Timby et al.* [13] (Sweden) 2015 | Double-blind RCT ITT analysis | Healthy infants <2 months of age, gestational age 37–42 weeks, birth weight 2500–4500 g | Inclusion: 240 infants Completed: 6 months of age: 92% - 80% BF - 80% SF | Analysis at: - 4 months of age: 92.5% - 6 months of age: 92% - 12 months of age: 92% | Intervention: Experimental formula supplemented with protein-rich bovine MFGM (Lacprodan MFGM-10, Arla Foods Ingredients) Duration: From enrollment <2 months to 6 months of age, follow-up until 12 months of age | (1) Standard formula (2) Breastfeeding (reference group) | At inclusion, 4, 6, 12 months of age | Serum lipids, adipokines, homeostasis, inflammatory biomarkers, and blood pressure | (1) Until 6 mo, the EF group had higher total serum cholesterol concentration than the SF group, reaching the level of the RR group (2) Blood pressure did not differ significantly between groups |
| Timby et al.* [11] (Sweden) 2015 | Double-blind RCT ITT analysis | Healthy infants <2 months of age, gestational age 37–42 weeks, birth weight 2500–4500 g | Inclusion: 240 infants - 80 SF - 80 BF | Analysis at: - 6 months of age: 93% - 12 months of age: 75% | Intervention: Experimental formula supplemented with protein-rich bovine MFGM (Lacprodan MFGM-10, Arla Foods Ingredients) Duration: From enrollment <2 months to 6 months of age, follow-up until 12 months of age | (1) Standard formula (2) Breastfeeding (reference group) | (1) Diarrhea filled by parent until 6 and 12 months of age (2) IgG to pneumococci until 6 and 12 months of age (3) EF group had lower s-IgG serotypes 1, 5, and 14 compared with the SF group |

Note: EF = Experimental Formula, SF = Standard Formula, RRH = Reduced Risk of Hospitalization, RVD = Respiratory Viral Disease, ACD = Acute Respiratory Diseases, BFR = Breastfeeding, AUC = Area Under the Curve, SF = Standard Formula, RR = Reduced Risk, NA = Not Available.
| Study ID       | Study Design and Analysis Method                  | Population                                           | Sample size + FU (%) at the End of Intervention or Specific Assessment Point | Intervention and Duration                                                                 | Comparison                                                                 | Measurement Points                                                                 | Primary Outcomes                                                                 | Secondary Outcomes                                                                 | Results                                                                 |
|---------------|---------------------------------------------------|------------------------------------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Timby et al.* [16] (Sweden) 2017 | Double-blind RCT Analysis of randomly selected infants | Healthy infants <2 months of age, gestational age 37–42 weeks, birth weight 2500–4500 g | Inclusion: 240 infants - 80 EF - 80 SF - 80 BF Analysis at: - 4 months of age: 82% - 12 months of age: 68% | Intervention: Experimental formula supplemented with proinflammatory MFGM (Lacprodan MFGM-10, Arla Foods Ingredients) Duration: From enrollment to 6 months of age | (1) Standard formula (2) Breastfeeding (reference group) | Control visits at 4 and 12 months of age | Oral microbiota composition | NA | (1) The species richness did not differ between the EF and SF group at 4 or 12 months of age. (2) BF group had significantly lower species richness oral microbiota than the formula-fed groups at 4 and 12 months of age. |
| Grip et al.* [17] (Sweden) 2018 | Double-blind RCT Analysis of the serum and plasma of randomly selected infants from each group | Healthy infants <2 months of age, gestational age 37–42 weeks, birth weight 2500–4500 g | Inclusion: 240 infants - 80 EF - 80 SF - 80 BF Analysis at: - 4 mo. of age: 90 randomly chosen infants - 6 months of age: 80% of infants - 12 months of age: 93 randomly chosen infants | Intervention: Experimental formula supplemented with proinflammatory MFGM (Lacprodan MFGM-50, Arla Foods Ingredients) Duration: From enrollment to 6 months of age, follow-up until 12 months of age | (1) Plasma lipidome and erythrocyte membrane lipidome at 6 months | Blood samples were collected at 4, 6, and 12 months of age and were obtained ≥2 h after the latest meal in randomly selected infants | Oral microbiota composition | NA | There were significant differences in the serum/plasma lipidome at 4 and 6 months of age in infants fed EF compared to infants fed SF. This separation was also detected in erythrocyte membranes at 6 months, but it did not remain in sera collected at 12 months of age 6 months after the end of the intervention. |
| He X. et al.* [18] (Sweden) 2019 | Double-blind RCT Analysis of the serum and plasma of randomly selected infants from each group | Healthy infants <2 months of age, gestational age 37–42 weeks, birth weight 2500–4500 g | Longitudinal assessment: 90 randomly selected infants out of 240 Cross-sectional assessment: 212 infants out of 240 | Intervention: Experimental formula supplemented with proinflammatory MFGM (Lacprodan MFGM-50, Arla Foods Ingredients) Duration: From enrollment to 6 months of age, follow-up until 12 months of age | (1) Standard formula (2) Breastfeeding (reference group) | At enrollment, 4, 6, 12 months of age: serum for longitudinal assessment 6 months of age- plasma for cross-sectional assessment | Metabolome | NA | (1) Formula-fed infants had higher levels of amino acid catabolism by-products and a low efficiency of amino acid clearance (preference for protein metabolism) (2) BF infants had higher levels of fatty acid oxidation products (preference for fat metabolism). |
| He X. et al.* [19] (Sweden) 2019 | Double-blind RCT Analysis of fecal microbiota and metabolome of randomly selected infants from each group | Healthy infants <2 months of age, gestational age 37–42 weeks, birth weight 2500–4500 g | Randomly selected subset of 90 infants (30 females and 30 males from each group: BF, SF, and BF) out of 240 infants | Intervention: Experimental formula supplemented with proinflammatory MFGM (Lacprodan MFGM-50, Arla Foods Ingredients) Duration: From enrollment to 6 months of age, follow-up until 12 months of age | (1) Standard formula (2) Breastfeeding (reference group) | At enrollment, 4, 6, 12 months of age | Fecal microbiome and metabolome | NA | (1) Fecal metabolite of BF-fed infants showed a significant reduction of lactate, succinate, amino acids, and their derivatives compared to SF-fed infants. (2) Introduction of weaning food with either human milk or infant formula reduces the distinct characteristics of breastfed or formula-fed infant fecal microbiome and metabolome profiles. |
| Study ID | Study Design and Analysis Method | Population | Sample size + FU (%) at the End of Intervention or Specific Assessment Point | Intervention and Duration | Comment | Measurement Points | Primary Outcomes | Secondary Outcomes | Results |
|----------|---------------------------------|------------|-----------------------------------------------------------------------------|--------------------------|---------|-------------------|-----------------|-------------------|---------|
| Breij et al. [22] (Belgium, France, the Netherlands, Singapore) 2019 | Double-blind RCT PP analysis | Healthy, term infants (gestational age 37–42), postnatal age ≤20 d, at birth weight between 10th and 90th percentiles | Inclusion: 333 infants - 115 EF - 109 SF - 88 BF Comprised: 76% of infants - 76% EF - 72% SF - 70% BF | Intervention: Experimental formula comprising large, milk phospholipid-coated dairy lipid droplets Duration: From enrolment: ≤35 days of age to 17 weeks of age | (1) Standard formula with small lipid droplets containing vegetable oils (2) Breastfeeding (reference group) | Baseline visit (≤35 day of age), 5, 8, 13, 17 weeks of age | Daily weight gain until 17 weeks of age | (1) Anthropometric measurements (2) Formula intake (3) Tolerance (4) Stool characteristics (5) Fat-soluble vitamins in plasma (6) Adverse events | (1) No relevant differences were observed in growth in all groups (2) Lower percentage of subjects with the atopic eczema in the EF compared with the SF group (p < 0.03) (3) No differences in plasma A and E vitamins concentration (p = 0.423, p = 0.82 respectively) |
| Li X et al. [13] (China) 2019 | Double-blind RCT ITT analysis | Healthy infants aged 21 ± 7 days with gestational age of 37–42 weeks at birth, birth weight >2500 g and <4000 g | Inclusion: 769 infants - 192 EF - 195 BF - 194 SF - 238 BF Comprised: 87% of infants - 87% EF - 88% BF - 90% SF | Intervention: (1) Experimental formula supplemented with probiotic-rich bovine MFGM (Lactopan MFGM-10, Arla Foods Ingredients) (2) Milk formula supplemented with L. paracasei strain F19 (Chr Hansen) Duration: From enrolment (21 ± 7 days) until 4 months of age | (1) Standard formula (2) Breastfeeding (reference group) | At baseline and at 1, 2, 3, 4, 5, 6, 9, 12 month of age | Incidence of infections, diarrhoea episodes and days with fever | (1) Anthropometric measurements (2) Safety and tolerability | (1) Mean weight for the breastfed group was significantly higher than for the EF group until age 2 months (p = 0.015 and 0.028 at 1 and 2 months, respectively) and for the SF and MFGM groups until age 4 months (all p < 0.041). After these ages’ infants showed no significant differences (2) Compared to the breastfed group, the SF infants had significantly more fever episodes (p = 0.021) and days with fever (p = 0.018), but not episodes of diarrhoea (3) Neither the MFGM nor the EF groups had significantly more episodes of fever or number of days with fever than the breastfed group |
| Li et al. [27] (China) 2019 | Double-blind RCT ITT analysis | Healthy, full-term infants, measurement 10–14 days of age at randomization, exclusively breastfed for at least 5 days before randomization, at birth weight of 2900–4000 g, singleton birth | Inclusion: 491 infants - 225 EF - 229 SF Comprised: 65% - 65% EF - 65% SF | Intervention: Experimental formula supplemented with proteic-rich bovine MFGM (Lactopan MFGM-10, Arla Foods Ingredients) and bovine lactoferrin Duration: From 10–14 day of age until 365 day of age | Standard formula | (1) Bayley-III at day 365 and MFGM groups until age 2 months (p = 0.021) and days with fever (p = 0.018), but not episodes of diarrhoea (3) Neither the MFGM nor the EF groups had significantly more episodes of fever or number of days with fever than the breastfed group |

**Table 1. Cont.**
Table 1. Cont.

| Study ID | Study Design and Analysis Method | Population | Sample size + FU (%) at the End of Intervention or Specific Assessment Point | Intervention and Duration | Comparison | Measurement Points | Primary Outcomes | Secondary Outcomes | Results |
|----------|----------------------------------|------------|--------------------------------------------------------------------------------|--------------------------|------------|---------------------|-----------------|-------------------|---------|
| Nieto-Ruiz et al. [20] (Spain) 2019 | Double-blind RCT PP analysis | Healthy 0–2-month-old full-term infants w/ adequate birth weight for gestational age, normal Apgar score | Inclusion: 220 infants: - 85 EF - 85 SF - 50 BF Complete: 64% of infants - 66% EF - 50% SF - 76% BF | Intervention: IF containing LCPUFAs AA, DHA, MFGM, symbiotics, gangliosides, nucleotides, and sialic acid Duration: From 0–2 mo. up to 18 months of age | (1) Standard formula (2) Breastfeeding (reference group) | (1) Baseline, 2, 3, 4, 6, 12, 18 months of age for anthropometric evaluation (2) Neurological development assessment at 2, 3, 4, and 12 months of age | (1) Weight, length, and subsequent body mass index (BMI) (2) Neurological Development (3) Visual Function | NA | (1) All infants presented an adequate neurological development up to 4 months of life, and no statistically significant differences were found between all the groups at any point in time |
| Nieto-Ruiz et al. [21] (Spain) 2020 | Double-blind RCT PP analysis | Healthy 0–2-month-old full-term infants w/ adequate birth weight for gestational age, normal Apgar score | Inclusion: 220 infants: - 85 EF - 85 SF - 50 BF Complete: 55% of infants - 50% EF - 54% SF - 66% BF | Intervention: IF containing LCPUFAs AA, DHA, MFGM, symbiotics, gangliosides, nucleotides and sialic acid Duration: From 0–2 months old up to 18 months of age | (1) Standard formula (2) Breastfeeding (reference group) | At 4 years of age | Assessments of oral language development in kindergarten children | NA | (1) Children who received IF seemed to show higher scores in the use of language \((p = 0.023)\) and oral spontaneous expression \((p = 0.024)\) than children who received SF (2) SF children presented lower scores in language content \((p = 0.026)\) and total score of PLON-R test \((p = 0.029)\) compared to BF children in an unadjusted model. After adjustment for selected confounding variables differences disappeared |

* Timby—one cohort; Nieto–Ruiz—one cohort; -RCT—Randomized controlled trial; -ITT—Intention to treat analysis; -PP—Per protocol analysis; -FU—Follow-up strength; -wks—Weeks; -EF—Experimental formula; -SF—Standard formula; -DHA—Docosahexaenoic acid; -AA—Arachidonic acid; -PF—Probiotic containing formula; -BF—Breastfeeding; -RV—Rotavirus; -RVD—Rotavirus diarrhea; -ACD—Any type of diarrhea; -Bayley-III—Bayley Scales of Infant and Toddler Development; -GDMS—Griffiths Mental Development Scale; -ASEBA—Achenbach System of Empirically Based Assessment; -LCPUFAs—Long-chain polyunsaturated fatty acids.
4. Discussion

The deepening understanding of complex communication between distinct organs, such as gut–brain and gut–lung axes, has expanded the significance of the breast milk to support the optimal cognitive and physical development of a child [28,29]. Therefore, unceasing efforts are being taken to create an infant formula mimicking the composition of the breast milk as closely as possible. It has been suspected that MFGM may be responsible for some of the advantageous properties of breastfeeding. Recently, a novel formula milk enriched with MFGM, naturally occurring in the maternal milk, was placed on the market. Numerous questions have been risen about the tangible evidence and whether to recommend it in the clinical setting. This infant milk is advertised as a product stimulating brain development, along with strengthening the immune system.

The beneficial role of MFGM has already been explored in animals and adults. Studies on rodent models have proven the impact of MFGM on infection, inflammation, brain composition, and gut barrier integrity, as well as intestinal development [30–34]. Interestingly, pups fed control formula demonstrated delayed intestinal growth, while the MFGM supplementation normalized intestinal crypt depths, epithelial cell proliferation, make-up of intestinal epithelial cell subsets, and resembled the make-up of intestinal microbes of mother’s milk-fed rats at the phylum level [34]. This finding may be specifically important for premature infants born with immature gastrointestinal tract, resulting in their higher risk of infections and a life-threatening Necrotizing Enterocolitis (NEC) [35]. Moreover, this study showed that the addition of MFGM also afforded significant protection to *Clostridium difficile* toxins, which may be an attractive feature as there is growing evidence that *C. difficile* is associated with diarrhea and prolonged hospitalization in younger children [34,36,37].

The results of our primary outcome meta-analyses have successfully confirmed that all the MFGM supplemented formulas have shown the non-inferiority when it comes to growth and weight parameters in children, or it even represented the results that were more similar to the breastfed groups. These conclusions had been anticipated beforehand, as formula feeding has been associated with infant’s increased weight gain velocity compared to breastfeeding [38,39]. Another key thing to remember is the very good safety profile of these formulas. Unfortunately, there is a small amount of evidence about the reported promising effects, which are fewer episodes of fever and lower need to use antipyretics, lower incidence of acute otitis media, reduction in episodes or duration of diarrhea, and improved cognitive development, which does not permit us to draw any firm conclusions about the effectiveness of MFGM supplementation in infants and children.

Yet, several issues have arisen during the assessment. Importantly, our findings revealed a limited number of pertinent clinical trials and a considerable heterogeneity among them. Firstly, although the composition of the milk formulas used was comparable, several different MFGM supplement products were applied in these trials. Due to the addition of other supplements enriching concept formulas along with MFGM, the results of two trials could not be analyzed equally [20,21,27]. The long-chain polyunsaturated fatty acids (LCPUFA) supplementation during pregnancy and/or lactation might be associated with a beneficial impact on child’s neurodevelopment [40,41]. Moreover, current evidence suggests that prophylactic use of lactoferrin, a protein found in cow and human milk, in preterm infants could significantly reduce the incidence of NEC [42]. Secondly, intervention duration and length of follow-up differed significantly between the studies. Thirdly, the experimental outcomes, such as an incidence of infection or makeup of the oral microbiome, were often inspected in individual trials [13,15,16]. Furthermore, cognitive development was evaluated with various measurement scales. Timby et al. used the Bayley-III score, while Li et al. employed the GMDS at different time points, making the outcomes harder to compare [11,13].

Our systematic review has several strengths. A key asset is a brief presentation, with a quantitative and qualitative synthesis of data, of the novel formula enrichment on the market. The thorough search of the most extensive databases complemented with seeking the information from conference abstracts, contacting study authors and experts in the field
makes it the most comprehensive summary of all experimental data about the use of MFGM in children up to date. Furthermore, this review provides an overview of currently ongoing trials registered at the ClinicalTrials, the EU Clinical Trials Register, and the Australian New Zealand Clinical Trials Registry (ANZCTR) (Table 2). Finally, when there is enough evidence, the mentioned supplementation could become an easy-to-use and cost-efficient add-on approach for many parents to support a child’s cognitive development and lower the prevalence of acute otitis media or fever episodes.

Table 2. Ongoing clinical trials on MFGM supplementation in children.

| Protocol ID, Trial Registry | Location       | Title                                                                 | Recruitment Status                          | Estimated Completion Date |
|-----------------------------|----------------|----------------------------------------------------------------------|---------------------------------------------|----------------------------|
| NCT04508257, ClinicalTrials.gov | China, Zhejiang | The Effect of a New Infant Formula on Growth and Cognition in Healthy Term Infants | Currently Recruiting                        | 28 February 2023           |
| ACTRN12620000552987, ANZCTR.org.au | Australia | Infant nutrition with milk fat globule membrane for infant cognition in early life | Not Yet Recruiting/Currently Recruiting    | 23 March 2024              |
| NCT02626143, ClinicalTrials.gov, PMC Pediatrics [43] | Chile | Effect of feeding mode on infant growth and cognitive function: study protocol of the Chilean infant Nutrition randomized controlled Trial (ChiNuT) | Recruitment Completed | NA                         |

NA—Not Applicable.

We are also aware of the limitations of our study. Trials presenting positive results are more eagerly published than those with negative results; therefore, this might be a source of positive-results bias. We could fully compare and contrast the findings of all included trials, as some of them assessed several supplements simultaneously.

5. Conclusions

Our review is the first systematic attempt to provide a valid answer to the question as to whether the present evidence is convincing enough to commend milk formulas enriched with MFGM. The currently available data signaled beneficial effects and a good safety profile, requiring future research with well-designed randomized double-blind placebo-controlled trials measuring the outcomes in a more unified way.

Supplementary Materials: The following are available online at https://www.mdpi.com/2072-6643/13/3/714/s1, Figure S1: Risk of bias assessment visualized using ROBVIS tool, Table S1: Pubmed search strategy.

Author Contributions: Conceptualization, D.A. and M.R.; methodology, D.A., K.D., P.D. and M.R.; software, D.A., K.D. and M.R.; validation, D.A., K.D., P.D. and M.R.; formal analysis, D.A. and K.D.; investigation, D.A.; resources, D.A.; data curation, D.A. and K.D.; writing—original draft preparation, D.A. and K.D.; writing—review and editing, P.D. and M.R.; visualization, D.A. and K.D.; supervision, P.D. and M.R.; project administration, D.A. and M.R.; funding acquisition, D.A. and M.R. All authors have read and agreed to the published version of the manuscript.

Funding: The research was not funded externally. The publication charge of the article was funded by Medical University of Warsaw.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.

References

1. Gila-Diaz, A.; Arribas, S.M.; Alzaga, A.; Martin-Cabrejas, M.A.; Lopez de Pablo, A.L.; Saenz de Pabion, M.; Ramiro-Cortijo, D. A Review of Bioactive Factors in Human Breastmilk: A Focus on Prematurity. *Nutrients* 2019, 11, 1307. [CrossRef]

2. Howie, P.W.; Forsyth, J.S.; Ogston, S.A.; Clark, A.; Florey, C.D. Protective effect of breast feeding against infection. *BMJ* 1990, 300, 11–16. [CrossRef]

3. Saarinen, U.M.; Kajosaari, M. Breastfeeding as prophylaxis against atopic disease: Prospective follow-up study until 17 years old. *Lancet* 1995, 346, 1065–1069. [CrossRef]

4. German, J.B. Dietary lipids from an evolutionary perspective: Sources, structures and functions. *Matern. Child Nutr.* 2011, 7 (Suppl. 2), 2–16. [CrossRef] [PubMed]

5. Demmelmaier, H.; Koletzko, B. Lipids in human milk. *Best Pract. Res. Clin. Endocrinol. Metab.* 2018, 32, 57–68. [CrossRef]

6. Manoni, M.; Di Lorenzo, C.; Ottoboni, M.; Tretola, M.; Pinotti, L. Comparative Proteomics of Milk Fat Globule Membrane (MFGM) Proteome across Species and Lactation Stages and the Potentials of MFGM Fractions in Infant Formula Preparation. *Foods* 2020, 9, 1251. [CrossRef]

7. Norris, G.H.; Milard, M.; Michalski, M.-C.; Blesso, C.N. Protective properties of milk sphingomyelin against dysfunctional lipid metabolism, gut dysbiosis, and inflammation. *J. Nutr. Biochem.* 2019, 73, 108224. [CrossRef] [PubMed]

8. Hernell, O.; Timby, N.; Domellöf, M.; Lönnerdal, B. Clinical Benefits of Milk Fat Globule Membranes for Infants and Children. *J. Pediatr. Gastroenterol. Nutr.* 2009, 49, e100097. [CrossRef] [PubMed]

9. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Group, T.P. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med.* 2009, 6, e100097. [CrossRef] [PubMed]

10. Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Coulton, I.; Cates, C.J.; Cheng, H.-Y.; Corbett, M.S.; Eldridge, S.M.; et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ* 2019, 366, i4898. [CrossRef]

11. Timby, N.; Domellöf, E.; Hernell, O.; Lönnerdal, B.; Domellöf, M. Neurodevelopment, nutrition, and growth until 12 mo of age in infants fed a low-energy, low-protein formula supplemented with bovine milk fat globule membranes: A randomized controlled trial. *Am. J. Clin. Nutr.* 2014, 99, 860–868. [CrossRef]

12. Billeaud, C.; Puccio, G.; Saliba, E.; Guillois, B.; Vaysse, C.; Pecquet, S.; Steenhout, P. Safety and tolerance evaluation of milk fat globule membrane-enriched infant formulas: A randomized controlled multicenter non-inferiority trial in healthy term infants. *Clin. Med. Insights Pediatr.* 2014, 8, 51–60. [CrossRef]

13. Li, X.; Peng, Y.; Li, Z.; Christensen, B.; Heckmann, A.B.; Stenlund, H.; Lönnerdal, B.; Hernell, O. Feeding Infants Formula with Probiotics or Milk Fat Globule Membrane: A Double-Blind, Randomized Controlled Trial. *Front. Pediatr.* 2019, 7, 347. [CrossRef] [PubMed]

14. Timby, N.; Lönnerdal, B.; Hernell, O.; Domellöf, M. Cardiovascular risk markers until 12 mo of age in infants fed a formula supplemented with bovine milk fat globule membranes. *Pediatr. Res.* 2014, 76, 394–400. [CrossRef] [PubMed]

15. Timby, N.; Hernell, O.; Vaarala, O.; Melin, M.; Lönnerdal, B.; Domellöf, M. Infections in infants fed formula supplemented with bovine milk fat globule membranes. *J. Pediatr. Gastroenterol. Nutr.* 2015, 60, 384–389. [CrossRef] [PubMed]

16. Timby, N.; Domellöf, M.; Holgerson, P.L.; West, C.E.; Lönnerdal, B.; Hernell, O.; Johansson, I. Oral Microbiota in Infants Fed a Formula Supplemented with Bovine Milk Fat Globule Membranes—A Randomized Controlled Trial. *PLoS ONE* 2017, 12, e0169831. [CrossRef]

17. Grip, T.; Dyrlund, T.S.; Athonen, L.; Domellöf, M.; Hernell, O.; Hyötyläinen, T.; Knip, M.; Lönnerdal, B.; Orešić, M.; Timby, N. Serum, plasma and erythrocyte membrane lipodienes in infants fed formula supplemented with bovine milk fat globule membranes. *Pediatr. Res.* 2018, 84, 726–732. [CrossRef]

18. He, X.; Parenti, M.; Grip, T.; Domellöf, M.; Lönnerdal, B.; Hernell, O.; Timby, N.; Slupsky, C.M. Metabolic phenotype of breast-fed infants, and infants fed standard formula or bovine MFGM supplemented formula: A randomized controlled trial. *Sci. Rep.* 2019, 9, 339. [CrossRef]

19. He, X.; Parenti, M.; Grip, T.; Lönnerdal, B.; Timby, N.; Domellöf, M.; Hernell, O.; Slupsky, C.M. Fecal microbiome and metabolome of infants fed MFGM supplemented formula or standard formula with breast-fed infants as reference: A randomized controlled trial. *Sci. Rep.* 2019, 9, 11589. [CrossRef]

20. Nieto-Ruiz, A.; García-Santos, J.A.; Bermúdez, M.G.; Herrmann, F.; Diééguez, E.; Sepúlveda-Valbuena, N.; García, S.; Miranda, M.T.; De-Castellar, R.; Rodríquez-Palmero, M.; et al. Cortical Visual Evoked Potentials and Growth in Infants Fed with Bioactive Compounds-Enriched Infant Formula: Results from COGNIS Randomized Clinical Trial. *Nutrients* 2019, 11, 2456. [CrossRef]

21. Nieto-Ruiz, A.; Diééguez, E.; Sepúlveda-Valbuena, N.; Catena, E.; Jiménez, J.; Rodríquez-Palmero, M.; Catena, A.; Miranda, M.T.; García-Santos, J.A.; Bermúdez, M.G.; et al. Influence of a Functional Nutrients-Enriched Infant Formula on Language Development in Healthy Children at Four Years Old. *Nutrients* 2020, 12, 535. [CrossRef]

22. Breij, L.M.; Abrahamse-Berkeveld, M.; Vandenplas, Y.; Jespers, S.N.J.; de Mol, A.C.; Kho, P.C.; Kalenga, M.; Peeters, S.; van Beek, R.H.T.; Norbruins, O.F.; et al. An infant formula with large, milk phospholipid-coated lipid droplets containing a mixture of dairy and vegetable lipids supports adequate growth and is well tolerated in healthy, term infants. *Am. J. Clin. Nutr.* 2019, 109, 586–596. [CrossRef] [PubMed]
23. Veereman-Wauters, G.; Staelens, S.; Rombaut, R.; Dewettinck, K.; Deboutte, D.; Brummer, R.-J.; Boone, M.; Le Ruyet, P. Milk fat globule membrane (INPULSE) enriched formula milk decreases febrile episodes and may improve behavioral regulation in young children. *Nutrition* 2012, 28, 749–752. [CrossRef] [PubMed]

24. Zavaleta, N.; Kvistgaard, A.S.; Graverholt, G.; Respicio, G.; Guita, H.; Valencia, N.; Lönnerdal, B. Efficacy of an MFGM-enriched complementary food in diarrhea, anemia, and micronutrient status in infants. *J. Pediatr. Gastroenterol. Nutr.* 2011, 53, 561–568. [CrossRef] [PubMed]

25. Gurnida, D.A.; Rowan, A.M.; Idrjadiatina, P.; Muchtadi, D.; Sekarwana, N. Association of complex lipids containing gangliosides with cognitive development of 6-month-old infants. *Early Hum. Dev.* 2012, 88, 595–601. [CrossRef]

26. Poppitt, S.D.; McGregor, R.A.; Wiessing, K.R.; Goyan, V.K.; Chitkara, A.J.; Gupta, S.; Palmano, K.; Kuhn-Sherlock, B.; McConnell, M.A. Bovine complex milk lipid containing gangliosides for prevention of rotavirus infection and diarrhoea in northern Indian infants. *J. Pediatr. Gastroenterol. Nutr.* 2014, 59, 167–171. [CrossRef]

27. Moukarzel, S.; Dyer, R.A.; Garcia, C.; Wiedeman, A.M.; Boyce, G.; Weinberg, J.; Keller, B.O.; Elango, R.; Innis, S.M. Milk Fat Globule Membrane Supplementation in Formula-Fed Rat Pups Improves Reflex Development and May Alter Brain Lipid Composition. *Sci. Rep.* 2018, 8, 15277. [CrossRef] [PubMed]

28. Fung, T.C.; Olson, C.A.; Hsiao, E.Y. Interactions between the microbiota, immune and nervous systems in health and disease. *Nat. Neurosci.* 2017, 20, 145–155. [CrossRef]

29. Budden, K.F.; Gellatly, S.L.; Wood, D.L.A.; Cooper, M.A.; Morrison, M.; Hansbro, P.M. Emerging pathogenic links in rats by inhibiting mucosal pathogen adherence. *Br. J. Nutr.* 2012, 108. [CrossRef]

30. Strong, R.C.; Hulstein, M.F.; Lamers, T.T.; van der Meer, R. Sweet buttermilk intake reduces colonisation and translocation of *Listeria monocytogenes* in mice treated with lipopolysaccharide. *J. Dairy Sci.* 2011, 94, 2201–2212. [CrossRef]

31. Snow, D.R.; Ward, R.E.; Olsen, A.; Jimenez-Flores, R.; Hintze, K.J. Membrane-rich milk fat diet provides protection against gastrointestinal leakiness in mice treated with lipopolysaccharide. *Nutrients* 2012, 4, 232. [CrossRef] [PubMed]

32. Moukarzel, S.; Dyer, R.A.; Garcia, C.; Wiedeman, A.M.; Boyce, G.; Weinberg, J.; Keller, B.O.; Elango, R.; Innis, S.M. Milk Fat Globule Membrane Supplementation in Formula-Fed Rat Pups Improves Reflex Development and May Alter Brain Lipid Composition. *Sci. Rep.* 2018, 8, 15277. [CrossRef] [PubMed]

33. Yu, Z.; Li, Y.; Niu, Y.; Tang, Q.; Wu, J. Milk Fat Globule Membrane Enhances Colonic–Mucus-Barrier Function in a Rat Model of Short-Bowel Syndrome. *J. Parenter. Enter. Nutr.* 2020, 1. [CrossRef] [PubMed]

34. Bhinder, G.; Allaire, J.M.; Garcia, C.; Lau, J.T.; Chan, J.M.; Rydz, N.R.; Bosman, E.S.; Graef, F.A.; Crowley, S.M.; Celiberto, L.S.; et al. Milk Fat Globule Membrane Supplementation in Formula Modulates the Neonatal Gut Microbiome and Normalizes Intestinal Development. *Sci. Rep.* 2017, 7, 45272. [CrossRef] [PubMed]

35. Neu, J.; Walker, W.A. Necrotizing Enterocolitis. *N. Engl. J. Med.* 2011, 364, 255–264. [CrossRef]

36. Sammons, J.S.; Toltzis, P.; Zautis, T.E. *Clostridium difficile* Infection in Children. *JAMA Pediatr.* 2013, 167, 567. [CrossRef]

37. Na, J.Y.; Park, J.M.; Lee, K.S.; Kang, J.O.; Oh, S.H.; Kim, Y.J. Clinical Characteristics of Symptomatic *Clostridium difficile* Infection in Children: Conditions as Infection Risks and Whether Probiotics Is Effective. *Pediatr. Gastroenterol. Hepatol. Nutr.* 2014, 17, 232. [CrossRef] [PubMed]

38. Appleton, J.; Russell, C.G.; Laws, R.; Fowler, C.; Campbell, K.; Denney-Wilson, E. Infant formula feeding practices associated with rapid weight gain: A systematic review. *Matern. Child Nutr.* 2018, 14, e12602. [CrossRef] [PubMed]

39. Azad, M.B.; Vehling, L.; Chan, D.; Klopp, A.; Nickel, N.C.; McGavock, J.M.; Becker, A.B.; Mandhane, P.J.; Turvey, S.E.; Moraes, T.J.; et al. Infant Feeding and Weight Gain: Separating Breast Milk from Breastfeeding and Formula from Food. *Pediatrics* 2018, 142, e20181092. [CrossRef]

40. Dziechciarz, P.; Horvath, A.; Szajewska, H. Effects of n-3 long-chain polyunsaturated fatty acid supplementation during pregnancy and/or lactation on neurodevelopment and visual function in children: A systematic review of randomized controlled trials. *J. Am. Coll. Nutr.* 2010, 29, 443–454. [CrossRef]

41. Taylor, R.M.; Fealy, S.M.; Bisquera, A.; Smith, R.; Collins, C.E.; Evans, T.-J.; Hure, A.J. Effects of Nutritional Interventions during Pregnancy on Infant and Child Cognitive Outcomes: A Systematic Review and Meta-Analysis. *Nutrients* 2017, 9, 1265. [CrossRef] [PubMed]

42. He, Y.; Cao, L.; Yu, J. Prophylactic lactoferrin for preventing late-onset sepsis and necrotizing enterocolitis in preterm infants: A PRISMA-compliant systematic review and meta-analysis. *Medicine* 2018, 97, e11976. [CrossRef] [PubMed]

43. Toro-Campos, R.; Algarín, C.; Peirano, P.; Peña, M.; Murguia-Peniche, T.; Wu, S.S.; Uauy, R. Effect of feeding mode on infant growth and cognitive function: Study protocol of the Chilean infant Nutrition randomized controlled Trial (ChiNuT). *BMC Pediatr.* 2020, 20, 225. [CrossRef] [PubMed]